IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.666
AS - Asia 2.322
EU - Europa 1.860
SA - Sud America 211
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 7.087
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.615
CN - Cina 1.486
IE - Irlanda 516
SG - Singapore 457
UA - Ucraina 368
DE - Germania 261
FI - Finlandia 244
HK - Hong Kong 205
RU - Federazione Russa 182
BR - Brasile 179
SE - Svezia 102
IT - Italia 71
GB - Regno Unito 49
VN - Vietnam 48
CA - Canada 36
IN - India 30
FR - Francia 18
IQ - Iraq 16
BD - Bangladesh 13
MX - Messico 11
NL - Olanda 11
AR - Argentina 10
JO - Giordania 10
PL - Polonia 10
TR - Turchia 9
ZA - Sudafrica 9
EC - Ecuador 7
LT - Lituania 7
IR - Iran 6
JP - Giappone 6
VE - Venezuela 6
CL - Cile 4
EU - Europa 4
PK - Pakistan 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BE - Belgio 3
ES - Italia 3
MA - Marocco 3
NP - Nepal 3
NZ - Nuova Zelanda 3
AT - Austria 2
BB - Barbados 2
BO - Bolivia 2
GE - Georgia 2
ID - Indonesia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PY - Paraguay 2
AD - Andorra 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CO - Colombia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 7.087
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
Chandler 396
Nanjing 350
Beijing 226
Dallas 210
Hong Kong 205
Singapore 182
Ashburn 170
Nanchang 156
Boardman 149
Shenyang 121
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 100
Lawrence 95
Hebei 92
Medford 81
Tianjin 66
Los Angeles 58
Hangzhou 52
Munich 39
Buffalo 37
Helsinki 36
Redondo Beach 35
New York 25
Shanghai 25
Toronto 25
Moscow 24
Seattle 24
Norwalk 22
Turku 18
São Paulo 17
Ho Chi Minh City 14
Woodbridge 13
Fairfield 12
San Francisco 12
Des Moines 11
Jinan 11
Pune 11
Amman 10
Ann Arbor 10
Atlanta 10
Hanoi 10
Milan 10
Frankfurt am Main 9
Santa Clara 9
Johannesburg 8
Kunming 8
Dearborn 7
Orem 7
Warsaw 7
Baghdad 6
Belo Horizonte 6
Eindhoven 6
Lanzhou 6
London 6
Poplar 6
Verona 6
Brooklyn 5
Guangzhou 5
Ningbo 5
Quito 5
Rome 5
Taizhou 5
Tokyo 5
Washington 5
Chennai 4
Halifax 4
Montreal 4
Orange 4
Porto Alegre 4
Rio de Janeiro 4
Stockholm 4
Tehran 4
Zhengzhou 4
Boston 3
Brussels 3
Campinas 3
Curitiba 3
Dubai 3
Fuzhou 3
Manchester 3
Recife 3
Tashkent 3
Wroclaw 3
Wuhan 3
Ankara 2
Annapolis 2
Basra 2
Bishkek 2
Biên Hòa 2
Brasília 2
Bridgetown 2
Bắc Giang 2
Caracas 2
Carney 2
Charleston 2
Charlotte 2
Totale 4.709
Salva come PNG Salva come JPEG
Nome #
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 113
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 111
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 110
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 108
Comparison between orlistat and sibutramine in obese patients with mild hypertension 107
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 106
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 106
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 102
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 101
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 100
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 99
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 97
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 95
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 93
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 92
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 92
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 91
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 90
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 90
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 88
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 87
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 86
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 86
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 86
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 85
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 84
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 83
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 82
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 81
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 81
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 81
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 78
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 78
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 76
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 76
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 76
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 75
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 75
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 74
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 74
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 74
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 74
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 73
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 73
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 73
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 72
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 71
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 71
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 71
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 71
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 71
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 70
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 70
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 70
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 70
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 70
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 70
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 69
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 69
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 68
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 68
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 67
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 67
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 67
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 66
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 66
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 66
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 65
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 65
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 64
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 63
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 63
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 63
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 63
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 63
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 62
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 62
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 62
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 62
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 61
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 61
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 61
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 60
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 58
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 58
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 58
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 55
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 55
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 54
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 53
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 52
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 50
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 46
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 43
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 43
Totale 7.107
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021423 0 0 0 0 0 87 0 111 15 98 95 17
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/20251.068 8 107 46 37 10 31 61 77 262 6 115 308
2025/20261.294 261 175 261 217 267 113 0 0 0 0 0 0
Totale 7.107